Drug Approval | January 30, 2023
FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Cell sorting technology supports researchers advancing new therapies
Medical Tourism will boost India’s economy
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Subscribe To Our Newsletter & Stay Updated
